New method to measure blood coagulation in cancer patients
Application of a New Type of Whole Blood Coagulation Time Measurement in Evaluating the Hypercoagulable State of Malignant Tumors
This study is testing a new way to measure blood clotting in cancer patients to see if it can help doctors better understand and manage their risk of blood clots.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 354 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tianjin Medical University General Hospital Academic / other |
| Locations | 1 site (Tianjin, Tianjin) |
| Trial ID | NCT05939960 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates a novel coagulation time measurement system designed to assess the hypercoagulable state in patients with malignant tumors. The study focuses on measuring general clotting time (GCT), platelet-rich plasma clotting time (PRP-CT), and platelet-poor plasma clotting time (PPP-CT) to provide a more accurate evaluation of coagulation disorders in these patients. It aims to improve upon existing scoring systems that inadequately reflect the coagulation status of tumor patients. By identifying hypercoagulability more effectively, the study seeks to enhance patient management and outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with newly diagnosed or progressing solid malignant tumors and an expected survival time of more than six months.
Not a fit: Patients with known venous thrombosis or those who have undergone major surgery recently may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better risk assessment and management of thromboembolic events in cancer patients.
How similar studies have performed: While similar studies have explored coagulation in cancer patients, this specific approach using a new measurement system is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Voluntarily participate and sign an informed consent form; 2. Age ≥ 18 years old 3. Expected survival time\>6 months; 4. Patients diagnosed with malignant tumors for the first time or progressing during treatment; 5. Solid malignant tumors with clear pathological diagnosis; 6. ECOG physical fitness score ≤ 2 points Exclusion Criteria: 1. Patients with known venous thrombosis (including upper and lower limb venous thrombosis, Pulmonary embolism, visceral venous thrombosis, etc.); 2. Patients who have received long-term treatment with Warfarin, Rivaroxaban, and low-molecular-weight heparin (except aspirin, hydrogen Clopidogrel, etc.); 3. Patients with active infections and sepsis; 4. Hematology tumor (except lymphoma); 5. Patients who undergo any major surgical treatment within 28 days prior to enrollment;
Where this trial is running
Tianjin, Tianjin
- Tianjin Medical University General Hospital — Tianjin, Tianjin, China (Recruiting)
Study contacts
- Principal investigator: Zhang Jianning, Doctor — Tianjin Medical University General Hospital
- Study coordinator: donglai Jin, Doctor
- Email: zyyjgb_ll@163.com
- Phone: 862260363203
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.